Mutations in the TP53, CTNNB1, TERT promoter, AXIN1, ARID1A, and ARID2 genes are associated with the diagnosis and treatment of HCC patients (De Stefano et al., 2018). This evidence concerns the gene TP53 and hepatocellular carcinoma.